Goodman's group first suggested that tumour resistance to the anti-metabolite methotrexate might be exploited therapeutically (Goodman et al., 1964) . They had observed that tumour cells which developed resistance to this agent frequently had increased levels of the enzyme dihydrofolate reductase (Friedkin et al., 1962 (Mishra and Mead, 1972) . The results shown by these workers thus substantiate the principle of an enzymedependent regeneration of a faulty cofactor being a useful model for obtaining selective anti-tumour effects.
The investigation of acqutired drug resistance in animal tumours has led to the recognition of several possible mechanisms for resistance to any particular drug. The difficulty of obtaining suitable material for study from human tumours has prevented detailed investigation. However, Steuart and Burke (1971) (Koechlin et al., 1966) . This drug, which was originally synthesized by Heidelberger et al. (1957) and discarded as it had no useful anti-tumour effects, has in the last few years been found to be an effective anti-fungal agent. It seems clear that the toxicity of 5-fluorocytosine against fungi is due to their having an active deaminase which converts 5-fluorocytosine to 5-fluorouracil. This latter agent, following its metabolism to 5-fluorodeoxyuridine monophosphate, is an inhibitor of thymidylate synthetase. Thus, it is believed that the selective toxicity of 5-fluorocytosine in fungi and not in normal human cells is a consequence of the fungi possessing an enzyme which activates the drug to a lethal compound.
5-fluorocytosine has been used widely for the treatment of fungal disease during the past few years (Fass and Perkins, 1971) . Adverse reactions reported during 5-fluorocytosine treatment have been rare, although one or two patients have become severely thrombocytopenic and neutropenic while taking the drug. No satisfactory explanation of these toxicities has been suggested, nor is it apparent that these effects were seen in patients with leukaemia who had previously been treated with cytosine arabinoside for their primary disease.
The recognition that human leukaemic cells which have become resistant to cytosine arabinoside may contain increased cytidine deaminase activity (Steuart and Burke, 1971) indicates a potential therapeutic use for 5-fluorocytosine. In this context, it is reasonable to assume that the drug would be toxic only in those cells which contained high deaminase activity and that such cells would be leukaemic.
Preliminary studies in this laboratory of the cytidine kinase and deaminase activity of human leukaemic cells have shown that deaminase activity is increased in the leukaemic cells of some patients 27 who have been treated with cytosine arabinoside. It is planned to treat patients whose leukaemic cells have high cytidine deaminase activity with 5-fluorocytosine in the hope that this drug will be selectively toxic to their leukaemic clone of cells. It has also been observed that the cytidine kinase activity may be increased in cells with high deaminase activity, and it thus remains to be shown that the high deaminase activity reported by Steuart and Burke (1971) is more than a non-specific indication of an immature cell population being selected by chemotherapy, rather than a particular mechanism of resistance.
It is widely recognized in cancer chemotherapy clinics that while tumour cells may become resistant to repeated courses of cytotoxic therapy normal marrow and gut lining cells appear to maintain their sensitivity. It is this factor which usually limits the scale of chemotherapy in patients with drugresistant tumours, since the large doses of cytotoxic drugs which may be required to overcome resistance are not tolerated by the normal host tissues. However, this therapeutic impasse has specific chemotherapeutic possibilities in a very general sense also. This derives from the principle of therapeutic " rescue " which has been used widely during the last few years, particularly with the antifolate drug, methotrexate. The principle of this approach, as currently practised, is that an agent which damages rapidly proliferating cells, leading to cell death, may have less drastic effects in more slowly proliferating cells provided the duration of drug exposure is short (Bruce, Meeker and Valeriote, 1966) . Methotrexate, by blocking the enzyme dihydrofolate reductase, deprives cells of the reduced folate co-factors which are required for DNA synthesis (Osborne, Freeman and Huennekins, 1958) . Reduced folate (folinic acid) can be administered after a 24-36 hour methotrexate infusion, and this will immediately restore the folate pools in cells which have not been irreparably damaged by the folate depletion. Experience has indicated that this population of cells is composed mainly of normal and not tumour cells. Using this approach, impressive cancer therapeutic successes have been reported (Capizzi et al., 1970; Djerassi et al., 1972) .
In the case of methotrexate-resistant tumour cells and sensitive marrow and gut cells, methotrexate therapy will inhibit DNA synthesis in the normal cells but have little effect on the resistant tumour cells. In this situation, it seems possible that resistant tumour cells will be selectively sensitive to agents which lethally damage cells undergoing DNA synthesis. Thus, prior administration of a methotrexate infusion would protect normal cells from the lethal effects of subsequently administered cytosine arabinoside, and the cytosine arabinoside would be selectively toxic to the resistant cells synthesizing DNA. Following 24-36 hours of methotrexate infusion, the normal marrow and gut cells would be " rescued" with folinic acid.
Thus, the emergence of drug resistance in tumours may be turned to therapeutic advantage. It is clearly important that the mechanisms of cytotoxic drug action and resistance in human tumour cells should be studied, not only so that drugs may be administered in rational combination schedules, but also so that possible selective advantage may be taken of the potentiality of tumour cells to develop alternate metabolic paths.
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